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In the la,1 decade, several new antiarrhythmtc drug? hve 
become available for the ucatment of ventricular anhylh- 
mia. Because of demonstrated efficacy 01 intnvenous lidc- 
caine in the prophylaxis and treatment of ventricular 
arrhythmias asscciared with acute myocardial infer&n 
(I,Z), tocaktidee, an oral congener of lidoeaine with elec- 
trophysiologic properties similar to those of lidocaine, was 
believed 10 have much promise. Several investi!aors have 
reported its effectiveness ie the suppression of chronic 
ventricular premature depolarizations~~d treatment of ven- 
tricularankythmias associated with acute myofardial infarc- 
tion. There are, however, few &la (1.4) attesting to its 
ECG monttortng rump. Hiltmy ol previous myocardiat 
tofatiion md fatturr of respwse to lidwafne avrtkded 
with Pathore to respond to tc&nide. Side e&&s were 
pornmen both during initY therapy and duriag tong.term 
treatment and aece~ltated dbcrmllnuslion of tocainlde 
thrrspy In 17% oftiw psttents. At a ROPO fotlowp pried 
of 14 ,,vm,ks, 13 psti,r,,s are rtIu reeeivtng l.mh\de md 
are orrhylhmlP.frrr. 
In mt~dudm, Ibo ddnes d oral twtnldc In the 
DIIII~Z~RM~ ot drwrrtnstorp suslsilwd ventricular 
effcacy in patients with sustained ventricular tachycardia or 
fibrillation. 
This report describes our experience with toeainide in 
patients with previous drug-refractory sustained ventricular 
tackycardia DT fibrillation who were referred to the Univer- 
sity of Washington and Stanford University Medical Center. 
Methods 
Sttiy pntimlv. Tke study group consisted of 82 patients, 
all with a history of one or more episodes oi out of hospital 
ventricular fibrillation or symptomatic sustained ventricular 
tachycardia that was not caused by acute myocardial infarc- 
tion. electrolyte imbalance or a proarrhytkmic etfect of 
antiarrkyihmic therapy. The patients had previously failed 
one or more antiarrbythmic dmgs, defined as inabilky of the 
drug in therapeutic oncentrations to suppress pontaneous 
or inducible anhyihmia, or intolerance to the drug. Patients 
were admitted to the telemetry unit, and antiarrhvlhmic 
therapy was discontinued for a r&mum of five half-iives in 
preparation for baseline etectrophysiotogic study in the 
drug-free state. Digoxin, when !&d for coogesdve heart 
failure or for ventricular rate control duingatrial fibrillation, 
and betweceptor blockers and calcium channrl blockers, 
when used for angina or hypenension, were continued at a 
stable dose. Patienrs who developed frequent repetitive 
episodes of ventricular tachycardia in the drug-free state did because of incessant ventricular tachycardia were evaluated 
not undergo baseline electraphysiologic testing. but bad by contm~ow ECG monitoring. Tocamidc was discontinued 
therapy directed by Halter ambulatory electrocardiographic 9 patients developed intolerable side effects or had recur- 
(ECG) monitoring of spontaneous arrhythmias. rence of sonamed vemricutar tachycardia or fibrillation at a 
Eteetropbysiotogic study. Baseline etectropbys~otogx therapeutic toamide blood level. 
testing was performed in the postabsorptive nonsedated Crberia j.0, drug success tly rlec*rophgsiologic .srmfy 
state using two or three quadripolar catheters insened per- 
culaneously and positioned at the right venlricular apex and 
ww: 11 <6 beats of inducible ver~tricular tachycardia with 
His bundle positions. Progranlmed ventricular stimulation 
tocainide in a pa:ient who bad sustained ventricular achy- 
was performed by delivering singte, double and triple ex- 
cardia induced during bawline electrophysiologic tes!ing. 
trastimuli (S&: S,S,S,; S,S,S,S,, resp-xtivelyl at twce the 
and 21 4 beats of inducible ventricular tachycardia with 
diastolic threshold (52 mA) with 2.0 ms rectangular pulses. 
tocainide in a patient in whom nonsustained ventricular 
Tne stimulation protocol consisted of a minimum of two 
tachycnrdm was mduced at basebne tectrophysiologic test- 
basic drive cycle lengths (S,) and two right ventricular 
ing. 
stimulation sites. The end point of the study was induction of Porool drug success during rir~wo~hysiolo~ic study ws 
sustained ventricular tacbycardia or fibrillation. !f a non- d4iwdos II mduction of nonwtained ~enln~~lar tachycar- 
sustained ventricular tachycardia was induced. stimulation dia (>6 beats. <30 s) in a patient with sustained ventricular 
was continued. If polymorphic ventricular tachycardia or txhycardm induced during baseline electropbysiologic test- 
fibrillation was induced in a patient with a history of Mona ing. and 21 induction of hemodynamicatty well tolerated 
morphic ventricular tachycardia. the mduclble ventncular sustained vemncular tachycardia with cycle length >toO ms 
fibrillation was considered to be a nonspecific response and longer than the cycle length of ventricular tachycardia 
stimulation was continued. induced during baeeline lectrophysiologic testing. 
Sustained ventricrrlar tachycordio WUE d&d as ventric- 4 aatbulamy ECG mmiforblg, the crireriafir rocoinide 
ular tachycardia >M s in duration or requiring temdnation ej%acy were I) total elimination of >3 beat ventricular 
because ofsymptomatic hypotension. Nonsustained ventric- racbycardn. or 2) in paticms who did not have ventricular 
ular tachycardia was defined as ventricular tachycardia of tachycardia during baseline monitoring. XII% reduction in 
r6 beats and <30 s in duration that temdnated spontane- the frequency of ventricular premature depolarization over 
ously. A positive electrophysiologic study was defined as 24b. 
reproducible induction of nonsustained or sustained ventric- Long-terns mcainide thempy was inidated in a!! the 
ular tachycardia t a rate of 2 It34 beatslmin. F’aiients with a patients in whom toeainide was judged to be etTcclivc or 
baseline negative electmphysiologic test were treated on the 
basis of findings of ambulatory ECG monitoring. in these 
partially effective by electrophysiolugic testing or KG 
individuals. a 24 hour Holtcr recording was obtained with 
monitoring. Patients wcrc followed up every I to 3 months in 
the patient drug free, and was analyzed for the frequency of 
the arrhythmiaclinic. andtocainidedorewasadjusted on the 
premature ventricular beats and episodes of ventricular 
basis of blood level and tolerance. Sudden death during 
tachycardia (a3 beats). 
follow-up study was defined as death occurring within I b of 
After completion of baseline evaluation, rocainide was 
the onset of symptoms. Nonfatal arrhythmia rceurrcncc was 
administered at a dose o/400 mgl8 h. Patients wcrc moni- 
defined as recurrence of sustained ventricular tachycardia or 
tored in the telemetry unit and were questioned daily for 
fibrillation from which the patient was successfully rcsusci- , 
possible adverse et&. Twelve lead 6.CGr were ob&cd 
daily. Tocainide blood levels were monitored at one of the 
cc&s (University of Washington) to monitor treatment, 
but not at the other center (Stanford University). The dose 
was increased or decreased on the basis of blood level and 
tolerance. Once a therapeutic toeainide blood level (5 to IO 
vrlmll or a maximal dailv dose of 2.40l mr was achieved, 
kt%ctiveness of drug therapy was evaluatedby repeat elec- 
trophysiologic testing or ambulatory ECG monitoring. The 
technique used to evaluate effectiveness of tocainide de- 
pended on the findings during baseline evaluation: patients 
can predict response to tocainidc. Lidwaine was considered 
to be et&live ifit comoletelv abolished 23 beat ventricular 
tachycardia nd coupI& and caused marked suppression of 
ventricular premature depolarization frequency tbrougbout 
the infusion period. During electmpbysiototic testing, crite- 
ria for lidocaine eUiacy were the same as those for toain- 
with a baseline positive electrophysiologic test undcrwcnt ide. 
repeat electraphysiologic testing. whereas patients with a Swisties. Statistical analysis was performed with at test 
negative baseline electraphysiologic test and those who did for paired and unpaired data and Fisher’s exact test. The 
not undergo electrophysiologic testing in the drug free state criterion for significance wasp 4 0.05. 
Figure 1. Study plan. In 54 patients. all with inducible ventricular 
tachycar*ia (VT) a* hbriltaion during base(ine elcctropbyrioiogic 
study (EPSI. treatment was guided by elrctrophysiologic tesdng, 
wkrear m 28 patieies with a negative electrophysiologic test or 
frequent spontaneous ventricular tacbyeardis. txatment was guided 
by ambulatory electrocardiographic Watery mordtorinp. Numbers 
in parentheses indicate the number of patients. 
Clinic~I feehlres of palients. Of the 82 patients in this 
study, 54 had a history of cardiac arrest and 28 had sustained 
ventricular tachycardia. There were 63 men and 19 women 
whose mean age was 62 z? 1 I years (range 21 0, 81). The 
cardiac diaanoaes were coronary artery disease in 12 pa- 
tients, con~stive cardiomyopathy in 3; valvular heart dis- 
ease in 3, mitral valve prolapse in 2 and congenital hefirt 
disease in 2. Sixty-five patients (7%) had a histoty of past 
myoeardial infarction, 37 (45%) had chronic angina and 12 
(88%) had a history cd congestive heart failure; 39% were in 
New York Heart Association functional class 111 or IV. The 
mean left ventricular eiectiun fraction, determined by con- 
trast or radionuclide aigiography, was 0.30 c 0.12 irange 
0.07 to 0.53). An average of 3.3 + 1.3 antiarrhythmic drugs 
had been ineffective in&h patient before to&de therapy 
was begun. 
Bawiine electropbysi&gic lindings. Seventy patients un- 
derwent baseline ekctrophyriologic testing; the remaining 
12 patients were not tested by electmphysiology because of 
frequent spontaneous ventricular tachycardia in the drug 
free state. Baseline ekctrophysiologic tests were positive in 
61 patients (87%) and negative in 9. The 9 patients with a 
negative electraphysiologic test and the I2 patients who did 
not undergo initial electrophysiologic testing were treated on 
the basis of ambulatory ECG (Holler) monitoring. In addi. 
tion, seven patients whose baseline electrophysiologic tests 
were positive, but who were not retested on tocainide 
because of severe congestive heart failure (5 patients) or 
patient refusal (2 patients), were also treated on the basis of 
ambulatory monitoring. Thus, 54 patients, all with inducible 
ventriculartachycardiaorfib~llationatbaselineelectmphysi- 
ologic testing, were treated by invasive ekctmphysiologic 
testing, and 28 patients were treated by noninvasive ECG 
monitoring techniques (Fig. I). Fifty-eight patients received 
tocainide alone and 24 patients received it in combination 
with another antiarrhythmic drug that had previously been 
ineffective by electrophysiologic study criteria when used 
alone. 
lnirial Results of Therupy 
Electmpbysialogic study 8rcmp. During baseline study. 
ventricular fibrillation was induced in 3 of the 54 wtients. 
sustained manomoQhic ventricular tachycardia in 46 and 
nonsustained ventricular tachycardia in 5. The arrhythmia 
was induced by a single extrastimulus in 7 patients, double 
extrastimuli in 25 and triple extrastimuli in 22. During the 
acute phase of tocainide therapy. four patients developed 
intolerable side effects necessitating discontinuation of the 
drtte. Tocainide was discontirtued in an additional (0 catients 
be&se of spontaneous recurrence of sustained ve&icular 
tachycardia or fibrillation with a documented therapeutic 
tocainide blood level. 
Fmy patients underwenr repear elecrrophysioiogic rest- 
ing while receiving rocainide; the study was positive in 33 
patients and negative in 7. Thus. of the 54 patients in the 
electraphysiologic study group, tocainide was et&live in 
otdv 7 (13%). In an additional live patients, tofainide was 
judged partially effective (in two b&se of marked prolon-
gation in ventricular tachycardia cycle length, and in the 
other three by virtue of induction of nonsustained ventricu- 
lar tachycardia rather than the sustained tachycardis in- 
duced at baseline electrophysiologic testing). Long-bmt 
tocainide therapy was continued in these I2 patients from 
the electraphysiologic study group in whom tacainide was 
judged to be effective or partially effective. During elec- 
rrophysiologic testing with to&tide, the induced arrhyth- 
mia was ventricular fibrillation in 2 oatients. sustained ven- 
tricular tacltycardia in 28 and &sustained ventricular 
tachycardia in 3. The cycle length ofthe induced ventricular 
fachycardia increased from 262 + 39 ms during baseline 
electrophysiologic testing to 31,b t 58 ms with to&tide (p < 
0.001). There was no significant change in heart raw. PR. 
QRS and QTc intervals or ventricular effectwe refractory 
period. 
Eleetroeardi~raphic manttoring roup. Twenty-eight pa- 
tients were treated on the basis of findings on ambulatory 
ECG monitoring. Four patients developed intolerable side 
effects, and twainide was considered to have faded in seven 
because of persistence of spontaneous ventricular tachycar- 
die during ambulatory monitoring. Tocainide was judged to 
he effective in the remaining 17 patients (61%). Long-term 
oral tocainide therapy was continued in all the I7 patients in 
whom it was judged to he e&ctive by ECG monitoring. 
Table I compares the clinical characteristics of the patients 
in the electrophysiologic study group and in the ECG mon- 
itoring group. The incidence of coronary artery disease and 
history of previous myocardial infarction was higher in the 
electrophysiologic study group. Otherwise, th:: average daily 
tacainide dose and clinical characteristics ( uch as age. sex. 
history, angina and congestive heart failure, functional class. 
nature of presenting arrhythmias. left vcntriculsr ejection 
fraction and number of pievious antiarrhythmic drug feil- 
ures) were similar in patients in the tw treatment groups. 
Overall results of tocainide therapy. Overall, tocainide 
was judged to &: effective in 24 (29%) of the 82 patients (in 
7 patients by electraphysiologic testing and in 17 patients by 
ambulatory ECG monitoring): in 5 patients it wes considered 
partially efiective. These 29 patients were continued on 
long-term tocainide therapy. Table 2 compares the clinical 
characteristics in the 29 patients who responded to tocainide 
with those of the 45 patients who did not. Thirteen (76%) of 
the 17 patients without prior myocardial infarction re- 
swnded to tocainide cornoared with lb 128%) of 57 with 
p’kious myocardial infer&n (p < O.W. Other clinical 
chxxteristics such as age, sex, presenting arrhythmia, the 
underlying cardiac disease, history of angina and congestive 
heart failure, left ventricular ejection fraction and daily 
towinide dose did not differ among responders and nonre- 
spenders. There were no differences in the tocainide dose or 
in the clinical characteristics of patients who responded to 
tacainide as compared with those who did not. 
The dora Rowe separarely examined in 54 pnrienrs wirh 
crrrdiac (~msr and 28 patienrs with rmained ventricular 
hrrhycordk The two groups were similar with reprd to age. 
sex, underlymg cardiac disease, history of angina and con- 
gestive heart failure and left ventricular ejection fraction. 
The therapy was directed by electraphysiologic testing in 
65% of the cardiac arrest group and 68% of the sustained 
ventricular tachycadia group. An overall tocainide success 
rate in the cardiac arrest group was 26% (14 of 54 patients) 
and 16% (IO of 28 patients) in the sustained ventricular 
tachycardia group (p = NS). 
Side effectr. Twenty-six patients reported side effecls 
during iniiial therapy; side effects were severe in eigst 
patients (10%) requiring a change in therapy (Table 3). The 
most comnwn side effects were neurologic and resolved on 
reducing the tocainide dose. The second most common side 
effects were nausea and vomiting: these were dose depa- 
dent and resolved in many patients if tocainide was admin- 
istered with a major meal. 
Comparative elieels of tocainide and lidocaine. Twenty- 
four patiems were mx~ted with !ocainide after receiving 
intravenous lidocaine inthecoronwycare unit(4patienta)or 
the electrophysiology laboratory (20 p&r&). Lidoeaine 
was judged to he effective in 12 pjiients during electrophy. 
siologic testing and in none of the patients who received it in 
Ihe corcmary care unit. Tocainide was found to he effective 
by electrophysiologic testing in 6 patients and ineffective in 
18 patients (by electrophysiologic testing in 17 patients and 
by ECG monitoring I patient) (Fig. 2). The response lo 
lidocaine and tocainide was concordant in 16 (67%) of the 24 
patients and discordant in 8 (33%) (p = 0.05). Five of the 12 
patients who responded to lidocaine also responded to 
tocainide, whereas I I of the 12 patients who failed to 
respond to lidacaine also failed to respond to tocainide 
(positive and negative predictive values of 42 and 92%. 
respectively). 
Lang-Term Therapy 
Tccnty-nine patients were discharged on oral tocainide 
therapy; 21 patients took tocainide as the only antiarrhyth- 
Figore 2. Relation between lidocaine and tocainide response. Five 
(41%) of 12 patients in whom Sdocaine was e&&e respaded to 
tocainide. whereas I I @Z%) of 12 patients who failed to rerpand to 
Sdocaine also failed to res~o** lo tocainide. Sensitivkv ’ = true 
F&we 3. Actuarial arrhythmia-free ~urwal in 26 pauentr who 
received long-term tocvinide therapy. Seven p&n,, had a recur. 
race of sustained arrhythmia tha! proved fatal in four. three 
padems died from nonarrhythmic causes and six patients had 
meainidediswndnued because uf ridr effects. The mean duraoon of 
follow-“P W&F 14 months (425 days,. 
mic agent and 6 took it in combination with other anti- 
atrhythmic drugs. The mean follow-up period was 14 months 
(range I lo 60). During follow-up stud). wen patients (24%) 
had recurrence of sustained arrhythmias (fatal in four) and 
three patients died from nonarrhythmic causes. Nine pa- 
tients reported side effects within 4 to 6 weeks of therapy 
(Table 3). In six of these patients, side effects pewsted even 
after the tocainide dose was reduced, necessitating a change 
in therapy, and another two patients had recurrence of 
arrhythmia at the reduced dose. Side effects during lang- 
term therapy were neurolagic disorders in seveo patients and 
skin rash in two. At a mean follow-up period of I4 months, 
13 (45%) of the 29 patients who were discharged an oral 
locainide therapy on the basis of iwhospital electiveness 
and tolerance were still receiving tocainide. The actuarial 
arrhythmia-free survival in this group is shown in Figure 3. 
Follw~up. Follow-up data were examined sepamtely for 
the electmphysiologic study and ambulatory ECG monitor- 
ing groups. Six ofthe seven patients in whom tocmmde was 
effective by electrophysiologic testing developed zide ef- 
fects. Only one patient could continue long-term tocainide 
therapy. Two of the five patients in whom tocainide was 
judged to be partially e6ective had a recurrence of sustained 
ventricular tachycardia (one patient had well tolerated stow 
ventricular tachycardia and the other patient had a cardiac 
arrest from which he was resuscitated). In the ECG moni- 
toring group, 5 (29%) of the I7 patients had a recurrence of 
sustained arrhythmia that was fatal in three. 
Discussion 
Comparison of results and previous studies. This study 
demonstrates that oral tocainide provides effective and well 
tolerated long-term therapy in only a small fraction of 
patients with previously drug-resistant sustained ventricular 
mchycardia or fibrillation. Under a management program 
that included both invasive and noninvasive techniquec for 
arrhythmia assessment. tacaimde was effective in 29% of 
patients during mitial evaluation and m 16% during long-term 
therapy. The low tacainide efficacy rate observed in these 
#cots wth drug-resistant ventncular mchycardia or Pbri- 
lation IS not ddferent from our ~revioos expencnce with 
other amiarrhythmic drug? (5) and the experience of other 
investigators (6.7) with similar patients. Most previous stud- 
ies (&I41 with tocainide were performed in-patients wits 
asymptomatic or minimally symptomatic ventricular premt 
we depolarizations and nonsustained ventricular tacbvcar- 
dia (S-i I) or in patients with ventricular arrhythmias &so- 
ciated with acute myocardial infarction (12-14). There are 
few reports (3.4.15) on the use of tocainide in high risk 
patients wth drug-resistant ventricular tachycardia or fihril- 
lation. 
Hanholser et al. (31 reported an overall success rate of 
46% during in-hospital evaluation in 228 patients with drug- 
refractory ventricular tachycardia or fibrillation. The re- 
sponse rate was 35% in 48 patients treated on the basis of 
electrophysiolojc testing and 49% in I80 patients treated by 
assessment with ambulatory ECG monitoring. In cordrast, 
we observed a 13 and 61% response rate by electrophysio- 
logic testing and ambulatory moniroring techniques. respec- 
tively. The- differences may, in part, be related to di6er- 
ewes m study group. study design and the criteria used to 
define drug success by electmphysiologie and ambulatory 
monitoring methods. In the study by Hanholser et al. (3) 
on!y those patients who did not qualify for the noninvasive 
treatment amroach because of infrequent ~oontaneous 
arrhythmias were t eated on the basis ofelectr&hyriologic 
testing. A positive electrophysiologic test was defined as 
induction of r3 beat vent&ular tachycardia, and patients 
with nonsustained ventricular tachycardia were also in- 
cluded in thetr study cohort. In contrast. the treatment in 
most of our patients was primarily guided by elecrrophysio- 
logic testing unless the baseline electrophysiologic test was 
negative or patients developed frequent and incessant spa- 
taneoos vetdricular tachycardii in the drug-free state. We 
used strict criteria to define drug success at electrophysio- 
Ionic testing, which may be reswnsible for the relatively low 
&ess rate that we observed boring such testing. The more 
stringent criteria used by Hanholser et al. (3) to define drug 
success by the noninvasive monitoring method may be 
responsible for lheir lower sttcces~ rate with this methcd. 
The tocainide reswnre rate was lower in oatients with a 
history of previous. myocardial infarction ihan in those 
without myocardial infarction--a finding similar to experi- 
ence with other aotiarrbythmic drugs (16). However. 30% of 
the 23 patientr who continued well tolerated smi “effective” 
tocainide therapy had a recurrence of sustained venlricul?~ 
tachycardia or fibrillation that proved fatal in 17%. The small 
number of patients who continued on long-term therapy 
prevents us from assessing the overall effectiveness of 
tocainide in improving survival in patients with drug- 
resistant malignant ventricular arrhythmias. 
Side effects. These were common during acute as well as 
long-term therapy; 32% of patients reported side effects 
during acute therapy and 31% developed side effects during 
long-term therapy. Most of the side effects were gastmintcs- 
tinal and ncurologic disorders and were not related to the 
total daily tocainide dose. Furthemwrc, all the patients who 
developed side effects during long-term therapy did so within 
I month of the start of treatment. with a tocainide dose that 
was well tolerated uring in-hospital treatment and at blood 
levels that were within therapwlic range. The high incidence 
of side effects observed by us is similar to that previously 
rewrted (3.4.10.14.15) and limits the widestwad use of 
t&ainide.’ 
Results in surtahwd ventricular tacbycardis w-sus wdiic 
arrest. The study group included patients with cardiac arrest 
.e_s well as those with sustained ventricular tachycardia. 
Because the mixing ofthese two seeminelv different anhvth- 
mia patient g&s can mask the r&l~ditTcrcncc in-the 
effectiveness of tocainide in the trestmcnt of one or the other 
type of arrhythmia, the data were separately examined in 
these two groups of patients. The overall FUEC~SS rate with 
tocainide was similar in patients with cardiac arrest and 
sustained ventricular tachycardia. Tocainide “failure” by 
electrophysiologic testing was defined in this study as con- 
tinued inducihility of the ventricular arrhythmia during pro- 
grammed stimulation in the patient receiving tocainide. 
Therefore, il is possible. as has been the experience with 
amiodarone. that the low snccess rate observed with tozin- 
ide mw raresent a limitation of the moerammed electrical 
stimulr&~ technique in the evaluaiioh of drug efdcacy. 
However. this possibility is unlikely because, in our study, 
the overall &livencss~of twain& in the patients tr&d 
by ambulatory ECG monitoring was also low. 
Lidocsine wsns lwainide in chronic ventricular arrhykh- 
mia. Although intravenous lidocaine is very effective for the 
prophylaxis and treatment of ventricular arrhythmia aswci- 
atcd with acute myocardial infarction, its eliicacv in the 
immediate treatme& of chronic ventricular arrhythmia is 
limited (171. We have also observed (5) limited usefulness of 
mexiktine. another lidocainelike druc. in the lreatment of 
sustained ventricular tachycardia or fiivillation that was not 
associated with acute myocardial infarction. Low etlicacv of 
tocainide and other cl&s IB antiarrhythmic drugs for.the 
treatment of chronic ventricular arrhythmia as opposed to 
arrhythmias associated with acute myocardial infarction 
may be partly related to the mechanism ofchronic ventricu- 
lar arrhythmias and the electroQhysiologic action of this 
class of antiarrhythmic drugs at the cellular level. The 
mechanism of recurrent sustained ventricular tachycardia or 
fibrillation in most instances is reentry. probably a result of 
inhomogeneous conduction and refrdctorincsr in the islands 
of viable myocardial cells commonly seen at the edge of an 
infarct. Lidocaine has little direct effect on sodium conduc- 
tance in such fully repolarized myocardial cells (18). In 
contrast. dnrinaacute mvocardial &hernia, mwardial cells 
are partially de&larircd; resulting in a dew& in the rate of 
rise of phase zero action potential (dV/dt) and conduction 
throngd the ischemic zone (19). Lidocaine restores resting 
membrane potential in these cells by augmenting repolariz- 
ing potassium current, thereby improving sodium condw 
tance and the conduction velocity. In this manner. it is likely 
to remove inhomogeneity of conduction between ischcmic 
and nonischemic myocardial tissues and to eliminate condi- 
tions for reentry. 
Response to li&wdne as a predictor of response to twain- 
lde. If response to an antiarrhythmic drug can be predicted 
on the basis of revponse to another drng that has similar 
elcctmphysiologic properties, the time and expense involved 
in managing patients with arrhythmias would be substan- 
tially decreased (Xl). We therefore xamined the response to 
lidocainc in our Qatients who received both agents. Lid* 
caine failure prc&ted failure of tocainide with high BCC’I- 
racy (91%), but lidocaine success did not assure a positive 
rcsponsc to tocainide. Tocainide was etrective in only 42% of 
patients who responded to lidocaine. These results are 
similar to those in previous reports (14,15,20). On the basis 
of these observations. we recommend that patients who 
have had failure oflidocaine therapy should not be evaluated 
with tocainide bccause the chance of tocainide success is 
very remote. fn contrast, patients who respond to lidocaine, 
have a better chance of responding to tocainide. However. 
because such concordance is far from perfect. response to 
tocainide should he individnallv evaluated toensure sncccss. 
Conclusions. In patients iith previously drug-resistant 
sustained ventricular tachycardia or fibrillation, the useful- 
ness of tocainide is limited by low effectiveness and frquent 
side effects. A small number of patients who tolerate tocain- 
ide during initial therapy develop delayed side effects, 
mostly related to the central nerwus spstem. Failure to 
MQOttd to lidoeaine predicts failure to respond lo locainide, 
but lidocaine snccess does not necessarily assure tocainide 
responsiveness. 

